Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Summit Technology (BEAM) -- Ignore unavailable to you. Want to Upgrade?

To: yosid who wrote (851)	4/23/1998 11:01:00 PM
From: GrandPohba	Read Replies (1) \| Respond to of 1386

Very well put, yosid.. I couldn't have said it better myself. These guys both could have had this market pretty much sewed up if they hadn't been so greedy, trying to hog the whole pie.Now there is competition on the horizon in Autonous(?is that correct?) and Sunrise, others....... Have you read the Value Line write up on BEAM? It is not very flattering. About the ONLY positive thing it had to say about BEAM was that they have a nice cash hoard, from the sale of shares shortly after gaining FDA approval. The time, money and energy that will be poured into litigation is a shame. I think the big winners here will be the treatment providers, as I have stated in the LCAV thread. GP

To: yosid who wrote (851)	4/25/1998 12:37:00 AM
From: John Binford, Jr.	Read Replies (1) \| Respond to of 1386

"If VISX thinks it can't happen to them, just read the ratings of the machines being tested and the projected sales prices against the price of a VISX laser (the new generation)." VISX is very very very aware that they must keep their technology the best and with their new upgrade they have. As for the projected sales price comment, what do you mean? Autonomous is basically a rental on a per procedure basis and they will charge the PPP fee (and hold it in escrow) on top of their rental fee. Do you not think that Visx will compete on price when the time comes? And what other company is spending more on R&D than Visx? Obviously, there will be competition in the future, but how will the new companies make money? They are all going to have to license the Summit and Visx patents, which isn't going to come cheap. And then they must compete head-to-head with Visx and Summit. Certainly, the companies can not recoup their investment and FDA costs from the laser sales alone. They will all have an associated per use fee like Visx and Summit. As for Summit never losing a lawsuit, well they have only won one, against Schwind for $800,000 or so. Visx settled with Summit on Azema last year, not because Summit would have won, but just to get on with business. Summit can never sue Visx again on Azema even if PPP is broken up. That alone was probably worth it to Visx. And Visx is still suing Summit for failing to pay proper machine royalties into PPP. And guess what, it is for $4.5 million. And the court date is May.